

100-200 Members of Congress, Families and Staff Treated with Ivermectin. No Hospitalizations

Protocol from Front Line COVID Critical Care Doctors

By [Sundance](#)

Global Research, October 13, 2021

[The Last Refuge](#) 9 October 2021

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

*This is beyond disturbing. According to **Dr Pierre Kory**, MD, MPA, and verified by the [Front Line COVID-19 Critical Care Alliance](#) (FLCCC), 100 to 200 congressional reps and/or staff and families who contracted COVID-19 were treated with the Front Line Ivermectin protocol. [\[LINK\]](#) and [\[LINK\]](#)*



This successful treatment is happening at the same time many congressional representatives are playing politics in favor of the vaccine; downplaying the effective anti-viral treatment and therapeutic approach with Ivermectin; and taking action to block regular American citizens from seeking similar treatment with Ivermectin.

Congress can seek treatment with a medication they simultaneously deny to others? This is well beyond a “scandal”, and needs to be investigated quickly.

Additionally, as Merck has announced a new and similar anti-viral drug called Molnupiravir, two trial studies in India have requested to exit the trials. Apparently the issue surrounds the new drug providing no benefit once a patient is moderately ill and hospitalized ([READ MORE, Reuters Link](#)).

Dr. John Campbell highlights a comparison between Ivermectin and Molnupiravir below:

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Zero Hedge

The original source of this article is [The Last Refuge](#)
Copyright © [Sundance](#), [The Last Refuge](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Sundance](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca